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INTRODUCTION
Breast and thyroid cancer occur at high rates among women. In 
2014, 24,632 and 18,304 Korean women developed thyroid and 
breast cancer, respectively, and the incidence of thyroid and breast 
cancer were 97 and 72.1 cases per 100,000 persons, or the highest 
and the second highest incidence of cancer in Korea, respectively 
[1]. 
The association between breast and thyroid cancer has been de-
bated for some time. Since Chalstrey and Benjamin [2] reported a 
high incidence of breast cancer as a secondary cancer among pa-
tients treated for thyroid cancer, additional studies have reported a 
relatively high incidence of secondary breast cancer compared to 
other secondary cancers, as well as an association between thyroid 
cancer and breast cancer [2,3]. Studies have also reported a high 
incidence of secondary thyroid cancer among patients treated for 
breast cancer [4-6]. Factors that have been suggested to contribute 
to this association include genetic factors shared between the two 
cancer types [5,7,8], environmental factors [9], hormonal influenc-
es [2,10-13], the influence of thyroid disorders (autoimmune dis-
ease) on the incidence of breast cancer [14], the effect of radioac-
tive iodine therapy following thyroid cancer surgery on the etiolo-
gy of breast cancer [15,16], and the effect of radiation therapy after 
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breast cancer surgery on the etiology of thyroid cancer [5,17,18].
However, a study has recently reported that radioactive iodine 
therapy after thyroid cancer surgery does not influence the inci-
dence of breast cancer [19], while another reported that based on 
the differences in the incidence of thyroid and breast cancer as sec-
ondary cancers, the physiological characteristics of each type of 
cancer and treatment-related factors contribute to the incidence of 
secondary cancers more significantly than the mutual risk factors 
for thyroid and breast cancer, including genetic factors [20]. There-
fore, the association between thyroid and breast cancer, as well as 
their characteristics, are still not clear [21,22].
It is important to invesigate the correlation between the types of 
cancer and their characteristics. The present study aimed to inves-
tigate the clinical and pathological characteristics of breast and 
thyroid cancer in patients who developed both types of cancer, and 
compare differences in the characteristics, outcomes, and causes of 
the two cancer types between two patient groups that differed by 
the order in which they developed each cancer. 
METHODS
In the present study, the medical records of patients who were di-
agnosed with thyroid and breast cancer as primary cancers and 
underwent both thyroidectomy and breast surgery at the Depart-
ment of Surgery of the Severance Hospital of Yonsei University 
College of Medicine were retrospectively analyzed. Patients who 
were diagnosed with distant metastasis or bilateral breast cancer, 
or who received treatment in a different hospital, were excluded. 
The number of surgeries performed for breast cancer at the De-
partment of Surgery of the Severance Hospital in the last 20 years 
was approximately 10,000, and that for thyroid cancer was around 
23,000. Among all patients treated, 405 patients were included in 
this study. The patients’ age, sex, pathological type of thyroid and 
breast cancer, cancer stage, surgery type and site, and postoperative 
adjuvant therapy were investigated. In addition, histological grade, 
estrogen receptor (ER), progesterone receptor (PR), and human 
epidermal growth factor receptor 2 (HER2) status were investigat-
ed in association with breast cancer. Extracapsular extension, mul-
tifocality, the BRAF V600E mutation, and histological thyroiditis 
were investigated in association with thyroid cancer. 
The patients were assigned to three different groups depending 
on the order of surgery they underwent for each cancer: the TB 
group for patients who underwent thyroidectomy then mastecto-
my, the S group for patients who underwent thyroidectomy and 
mastectomy at the same time, and the BT group for patients who 
underwent mastectomy followed by thyroidectomy. Characteris-
tics of breast and thyroid cancer were compared among the three 
groups. Patients whose surgeries for both cancers were timed less 
than 6 months apart from each other were included in the S group, 
and the remaining patients were placed in the TB or BT group. 
SPSS ver. 23.0 (IBM Inc., Armonk, NY, USA) was used for statis-
tical analysis. A chi-square test was used to analyze the nominal 
variables in each group, and a one-way ANOVA or independent 
t-test was used to analyze the continuous variables. For multivari-
ate analysis, the Bonferroni method was used. The Kaplan-Meier 
method was used for the survival analysis, and the log-rank test 
was used to compare variables. The nominal variables were ex-
pressed as proportions, and the continuous variables were ex-
pressed as mean and standard deviation. The level of statistical sig-
nificance was set at P < 0.05. 
The present study was approved by the Institutional Review 
Board of the Severance Hospital (IRB no., 4-2016-1018). 
RESULTS
The mean age of the patients at the time of being diagnosed with 
breast cancer was 50.9 ± 9.5 years, and ductal carcinomas were the 
most common pathological type of breast cancer, accounting for 
363 cases (89.6%). T1 and N0 were the most common stages of 
breast cancer accounting for 237 cases (58.5%) and 286 cases 
(70.6%), respectively. In the TNM classification, stage 1 was the 
most common, accounting for 177 cases (43.7%). In regards to his-
tological grades, 97 patients had grade I (24.0%), 168 (41.5%) had 
grade II, and 61 (15.1%) had grade III breast cancer. By receptor 
status, 70.6%, 55.3%, and 18.8% of all patients were ER, PR, and 
HER2 positive, respectively, and 70.4% of all patients underwent 
antihormonal therapy. Around half (45.7%) of all patients under-
went breast-conserving surgery, and 56.5% underwent radiation 
therapy after surgery (Table 1).
The mean age of the patients at the time of being diagnosed with 
thyroid cancer was 51.4 ± 9.7 years, and 201 patients (49.6%) were 
found to have other accompanying diseases such as thyroiditis on 
histological examination performed after thyroidectomy. Papillary 
carcinoma was the most common histological type, accounting for 
399 cases (98.5%), and TNM stage 1 was the most common stage, 
accounting for 233 cases (55.1%). There were 204 cases of extra-
capsular extension (50.4%). Of the total 405 patents, 61 patients 
were tested for the BRAF V600E mutation in their thyroid cancer, 
and of these, 45 (73.8%) had the BRAF V600E mutation. A total of 
161 patients (39.7%) underwent radioactive iodine therapy after 
thyroidectomy (Table 2).
The patients were divided into three groups according to the or-
der of surgeries they underwent after being diagnosed with breast 
and thyroid cancer to analyze the characteristics of both cancer 
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Table 1. Clinicopathologic characteristics of primary breast cancer 
Characteristic Total patients (n=405)
Age (yr) 50.9± 9.5
Histologic type
   Ductal
   Lobular
   Others
 
363 (89.6)
11 (2.7)
31 (7.7)
T stage
   Tis
   T1
   T2
   T3
 
60 (14.8)
237 (58.5)
100 (24.7)
8 (2)
N stage
   N0
   N1
   N2
   N3
 
286 (70.6)
89 (22)
20 (4.9)
10 (2.5)
TNM stage
   Stage 0
   Stage 1
   Stage 2
   Stage 3
 
56 (13.8)
176 (43.5)
142 (35.1)
31 (7.7)
Histologic grade
   I/II
   III
   Unknown
 
265 (65.4)
61 (15.1)
79 (19.5)
ER
   Negative
   Positive
   Unknown
 
111 (27.4)
286 (70.6)
8 (2)
PR
   Negative
   Positive
   Unknown
 
173 (42.7)
224 (55.3)
8 (2)
HER2
   Negative
   Positive
   Equivocal
   Unknown
 
273 (67.4)
76 (18.8)
29 (7.2)
27 (6.7)
Extent of surgery
   BCS
   TM
 
185 (45.7)
220 (54.3)
Neo-adjuvant chemotherapy
   Not done
   Done
 
360 (88.9)
45 (11.1)
Adjuvant chemotherapy
   Not done
   Done
 
177 (43.7)
228 (56.3)
Radiation therapy
   Not done
   Done
 
176 (43.5)
229 (56.5)
Hormone therapy
   Not done
   Done
   Unknown
 
114 (28.1)
285 (70.4)
6 (1.5)
Values are presented as mean±standard deviation or number (%). 
is, in situ; TNM, tumor node metastasis; ER, estrogen receptor; PR, progester-
one receptor; HER2, human epidermal growth factor receptor 2; BCS, breast 
conserving surgery; TM, total mastectomy.
Table 2. Clinicopathologic characteristics of primary thyroid cancer 
Characteristic Total patients (n=405)
Age (yr) 51.4± 9.7
Histologic type
   Papillary
   Follicular 
   Others
 
399 (98.5)
4 (1)
2 (0.5)
T stage
   T1
   T2
   T3
   T4
 
196 (48.4)
5 (1.2)
196 (48.4)
8 (2)
N stage
   N0
   N1a
   N1b
 
310 (76.5)
78 (19.3)
17 (4.2)
TNM stage
   Stage 1
   Stage 2
   Stage 3
   Stage 4
 
223 (55.1)
4 (1)
159 (39.3)
19 (4.7)
Capsular invasion
   Intrathyroidal
   Extrathyroidal
 
201 (49.6)
204 (50.4)
Multifocality
   Single lesion
   Multiple lesions
 
282 (69.6)
123 (30.4)
Tumor locationa)
   Ipsilateral
   Bilateral
 
140 (68)
66 (32)
Operation method
   Conventional
   Minimally invasive
 
381 (94.1)
24 (5.9)
Extent of surgery
   Less than bilateral total
   Bilateral total
 
199 (49.1)
206 (50.9)
Postoperative RAI therapy
   None
   Low dose
   High dose
 
244 (60.2)
139 (34.3)
22 (5.4)
Thyroiditis
   Absent
   Present
 
309 (76.3)
96 (23.7)
BRAF V600E mutation
   No mutation
   Mutation
   Unknown
 
16 (4)
45 (11.1)
344 (84.9)
Values are presented as mean±standard deviation or number (%). 
TNM, tumor node metastasis; minimally invasive, endoscopic or robotic thy-
roidectomy; RAI, radioactive iodine; BRAF, B-type Raf kinase.  
a)Patients undergoing bilateral total thyroidectomy. n= 206. 
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Table 3. Clinicopathologic characteristics of primary breast cancer based on order of incidence    
Characteristic TB (n=96) S (n=166) BT (n=143) P-value
Age (yr) 52.7± 10.1 50.8± 9.1 49.8± 9.2 0.073
Histologic type of breast cancer
   Ductal
   Lobular 
   Others
 
82 (85.4)
4 (4.2)
10 (10.4)
 
145 (87.3)
7 (4.2)
14 (8.4)
 
136 (95.1)
0
7 (4.9)
0.054
 
 
 
T stage
   Tis–1
   T2–4
 
81 (84.4)
15 (15.6)
 
126 (75.9)
40 (24.1)
 
90 (62.9)
53 (37.1)
0.001
 
 
N stage
   N0
   N1–3
 
80 (83.3)
16 (16.7)
 
117 (70.5)
49 (29.5)
 
89 (62.2)
54 (37.8)
0.002
 
 
TNM
   Stage 0–1
   Stage 2–4
 
70 (72.9)
26 (27.1)
 
98 (59)
68 (41)
 
64 (44.8)
79 (55.2)
< 0.001
 
 
Histologic grade
   I/II
   III
 
55 (80.9)
13 (19.1)
 
111 (79.9)
28 (20.1)
 
99 (83.2)
20 (16.8)
0.787
 
 
ER
   Negative
   Positive
 
24 (25)
72 (75)
 
38 (22.9)
128 (77.1)
 
49 (36.3)
86 (63.7)
0.027
 
 
PR
   Negative
   Positive
 
38 (39.6)
58 (60.4)
 
77 (46.4)
89 (53.6)
 
58 (43)
77 (57)
0.555
 
 
HER2
   Negative
   Positive
   Equivocal
 
74 (77.1)
17 (17.7)
5 (5.2)
 
122 (74.4)
29 (17.7)
13 (7.9)
 
77 (65.3)
30 (25.4)
11 (9.3)
0.306
 
 
 
Subtype
   ER+, HER2–
   ER+, HER2+
   ER–, HER2+
   ER–, HER2–
 
63 (65.6)
9 (9.4)
8 (8.3)
16 (16.7)
 
113 (68.9)
14 (8.5)
15 (9.1)
22 (13.4)
 
62 (52.5)
15 (12.7)
15 (12.7)
26 (22)
0.199
 
 
 
 
Extent of surgery
   BCS
   TM
 
59 (61.5)
37 (38.5)
 
82 (49.4)
84 (50.6)
 
44 (30.8)
99 (69.2)
< 0.001
 
 
Neo-adjuvant chemotherapy 
   Not done
   Done
 
89 (92.7)
7 (7.3)
 
139 (83.7)
27 (16.3)
 
132 (92.3)
11 (7.7)
0.023
 
 
Adjuvant chemotherapy
   Not done
   Done
 
61 (63.5)
35 (36.5)
 
72 (43.4)
94 (56.6)
 
44 (30.8)
99 (69.2)
< 0.001
 
 
Radiation therapy
   Not done
   Done
 
33 (34.4)
63 (65.6)
 
59 (35.5)
107 (64.5)
 
84 (58.7)
59 (41.3)
< 0.001
 
 
Hormone therapy (n= 399)
   Not done
   Done
 
22 (23.2)
73 (76.8)
 
43 (25.9)
123 (74.1)
 
49 (35.5)
89 (64.5)
0.074
 
 
Values are presented as mean± standard deviation or number (%).    
TB, thyroid cancer followed by breast cancer; S, simultaneous cancer; BT, breast cancer followed by thyroid cancer; is, in situ; TNM, tumor node metastasis; ER, 
estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; BCS, breast conserving surgery; TM, total mastectomy.
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types. 
In regards to the characteristics of breast cancer, the breast tu-
mors were significantly smaller, the extent of lymphatic invasion 
was significantly less, and the TNM was significantly lower in the 
TB group. Breast-conserving surgery was the most common type 
of surgery performed in the TB group, and the rate of postopera-
tive radiation therapy was also significantly higher. A small pro-
portion of patients in the TB group underwent postoperative che-
motherapy. The rate of preoperative chemotherapy was higher in 
the S group (Table 3).
Table 4. Clinicopathologic characteristics of primary thyroid cancer based on order of incidence    
Characteristic TB (n=96) S (n=166) BT (n=143) P-value
Age (yr) 48.6± 10.5 51.3± 9.2 53.4± 9.3 0.001
Histologic type
   Papillary
   Follicular
   Others
 
94 (97.9)
2 (2.1)
0
 
163 (98.2)
1 (0.6)
2 (1.2)
 
142 (99.3)
1 (0.7)
0
0.351
 
 
 
Tumor size
   ≤ 1 cm
   > 1 cm
 
60 (62.5)
36 (37.5)
 
119 (71.7)
47 (28.3)
 
117 (81.8)
26 (18.2)
0.004
 
 
T stage
   T1–2
   T3–4
 
43 (44.8)
53 (55.2)
 
87 (52.4)
79 (47.6)
 
71 (49.7)
72 (50.3)
0.494
 
 
N stage
   N0
   N1
 
70 (72.9)
26 (27.1)
 
128 (77.1)
38 (22.9)
 
112 (78.3)
31 (21.7)
0.611
 
 
TNM stage
   Stage 1-2
   Stage 3-4
 
57 (59.4)
39 (40.6)
 
97 (58.4)
69 (41.6)
 
73 (51)
70 (49)
0.322
 
 
Capsular invasion
   Intrathyroidal
   Extrathyroidal
 
41 (42.7)
55 (57.3)
 
87 (52.4)
79 (47.6)
 
73 (51)
70 (49)
0.291
 
 
Multifocality
   Single lesion
   Multiple lesions
 
67 (69.8)
29 (30.2)
 
118 (71.1)
48 (28.9)
 
97 (67.8)
46 (32.2)
0.825
 
 
Tumor location
   Ipsilateral
   Bilateral
 
75 (78.1)
21 (21.9)
 
139 (83.7)
27 (16.3)
 
120 (83.9)
23 (16.1)
0.44
 
 
Operation method
   Conventional
   Minimally invasive
 
85 (88.5)
11 (11.5)
 
161 (97)
5 (3)
 
135 (94.4)
8 (5.6)
0.02
 
 
Extent of surgery
   Less than bilateral total
   Bilateral total
 
36 (37.5)
60 (62.5)
 
75 (45.2)
91 (54.8)
 
88 (61.5)
55 (38.5)
0.001
 
 
Postoperative RAI therapy
   None
   Low (30 mCi)
   High
 
43 (44.8)
48 (50)
5 (5.2)
 
102 (61.4)
54 (32.5)
10 (6)
 
99 (69.2)
37 (25.9)
7 (4.9)
0.003
 
 
 
Thyroiditis
   Absent
   Present
 
71 (74)
25 (26)
 
127 (76.5)
39 (23.5)
 
111 (77.6)
32 (22.4)
0.805
 
 
BRAF V600E mutation (n= 61)
   No mutation
   Mutation
 
5 (35.7)
9 (64.3)
 
4 (22.2)
14 (77.8)
 
7 (24.1)
22 (75.9)
0.649
 
 
Values are presented as mean± standard deviation or number (%).    
TB, thyroid cancer followed by breast cancer; S, simultaneous cancer; BT, breast cancer followed by thyroid cancer; TNM, tumor node metastasis; RAI, radioactive 
iodine; BRAF, B-type Raf kinase. 
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In regards to the characteristics of thyroid cancer, the thyroid tu-
mors were smaller in the BT group; however, no significant differ-
ence in the N and TNM stages were found between the BT and the 
other groups. The rates of extracapsular extension and bilateral to-
tal thyroidectomy were significantly lower in the BT group. The 
BT group also had the highest proportion of patients (69.2%) who 
did not require radioactive iodine therapy (Table 4).
A survival analysis of breast cancer, thyroid cancer, and the first 
cancer to occur (the index tumor) was performed for the TB, S, 
and BT groups. The mean length of follow-up was 83.9 months, 
83.1 months, and 108.6 months, respectively, and no significant 
difference in survival rates was found among the groups. The rela-
tively short follow-up period for thyroid cancer and breast cancer, 
which have high survival rates, limited the survival analysis. The S 
group included patients whose surgeries for thyroid and breast 
cancer were separated by less than 6 months; this included some of 
the patients who developed breast cancer first (18 out of 166 pa-
tients, 10.8%), and who developed thyroid cancer first (14 out of 
166 patients, 8.4%) (Fig. 1).
DISCUSSION
Thyroid and breast cancer have the highest incidence among all 
types of cancer in women, and while studies have reported on an 
apparent association between these two cancers [2-6], their cor-
relation and characteristics are still not clear [21,22]. We analyzed 
and compared the pathological characteristics and outcomes of 
breast and thyroid cancer in patients who were treated for both 
types of cancer at a single institution according to the occurrence 
order of these cancers using a database of surgeries performed in 
the last 20 years for thyroid and breast cancer. We found a number 
of significant differences among the different groups of patients. 
Fig. 1. Overall survival curves. Curves are drawn from the diagnosis of 
(A) first developed any malignancy, (B) breast cancer, and (C) thyroid 
cancer. S, simultaneous cancer; TB, thyroid cancer followed by breast 
cancer; BT, breast cancer followed by thyroid cancer.
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First, the TNM stage of breast cancer decreased in the order of 
the TB, S, and BT groups (Table 3), and the rate of mastectomy was 
found to be BT (69.2%) > S (50.6%) > TB (38.5%) (P < 0.001). These 
results suggest that the rate of breast-conserving surgery was high 
among patients who were previously surgically treated for thyroid 
cancer possibly because breast cancer was detected early through 
regular medical examinations. The rate of postoperative radiation 
therapy according to the rate of breast-conserving surgery was the 
highest in the TB group (65.6%, P < 0.001), and the rate of postop-
erative chemotherapy was higher in the BT group, in which breast 
cancers were at relatively high TNM stages (69.2%) (P < 0.001). 
Therefore, the differences in the characteristics of breast cancer 
among the TB, S, and BT groups may be attributed to the different 
timing of discovering breast cancer during follow-up or through 
early screening.
However, considering the rate of ER positive breast cancer, it is 
possible that other factors contributed to the differences in the 
characteristics of breast cancer among the three groups. The rate of 
ER-positive breast cancer was 75%, 77.1%, and 63.7% in the TB, S, 
and BT groups, respectively (P = 0.027). While no significant dif-
ference in the rate of ER-positive breast cancer was found among 
the three groups, the higher mean age of the TB and S groups in 
comparison with the BT group may have translated to the slightly 
higher rates of ER+ breast cancer in these groups. Since a number 
of previous studies have suggested a correlation between thyroid 
cancer and ER expression [23-25], research on the effects of ER ex-
pression or estrogen on thyroid cancer is necessary. Chiappa et al. 
[26] previously reported a significantly high rate of ER+ breast 
cancer among patients with chronic thyroiditis in their study on 
the correlation between thyroid disorders and breast cancer. In the 
present study, no significant difference in the rate of thyroiditis was 
found among the groups. However, only a histological examina-
tion was used to assess thyroiditis after thyroid cancer surgery, and 
thus, our analysis on the correlation between thyroiditis and breast 
cancer was limited. It is important to investigate the effects of the 
pathways of thyroid hormones on the incidence of secondary 
breast cancer. 
In regards to the characteristics of thyroid cancer, the rate of thy-
roid tumors that measured less than 1 cm was the highest at 81.8% 
in the BT group (TB, 62.5%; S, 71.7%; P = 0.004), and the rate of less 
than bilateral total thyroidectomy was also the highest at 61.5% in 
the BT group (TB, 37.5%; S, 45.2%; P = 0.001). In addition, the pro-
portion of patients who did not undergo radioactive iodine thera-
py after thyroidectomy was the highest at 69.2% in the BT group 
(TB, 44.8%; S, 61.4%; P = 0.003). Therefore, the size of the thyroid 
tumor and the extent of surgery were less, and the rate of postoper-
ative adjuvant therapy was lower for the patients who were diag-
nosed with thyroid cancer after undergoing treatment for breast 
cancer (Table 4). This may be the result of early detection of thy-
roid cancer during postoperative follow-up and regular medical 
examinations as was the case in the study by Zhang et al. [27]. On 
the contrary An et al. [28] reported that patients who were diag-
nosed with both types of cancer at the same time had the smallest 
thyroid tumor size. Different follow-up protocols for patients with 
breast cancer among institutions and different treatment guide-
lines used among countries may have affected these results, and 
thus, additional research is necessary. 
The BRAF V600E mutation is the most commonly observed 
genetic change in papillary thyroid carcinomas, and it is an im-
portant factor in cell proliferation, differentiation, and apoptosis 
[29]. While it is known to be associated with not only thyroid can-
cer, but also malignant melanoma and other types of cancer [8], its 
association with breast cancer has not been clear, and thus, we 
conducted an additional analysis. Among all of the patients, 58 pa-
tients who were tested for the BRAF V600E mutation and had ER 
and HER2 test results were divided into 16 patients who did not 
have the mutation, and 42 patients who did. The rate of ER+ breast 
cancer was higher in the group without the BRAF mutation (88% 
vs. 81%). When the patients were further divided into four groups 
according to their ER and HER2 results, the rate of luminal breast 
cancer was slightly lower and the rate of triple negative breast can-
cer was slightly higher in the group with the BRAF V600E muta-
tion than the group without. However, because BRAF V600E test-
ing was only initiated recently and only thyroid cancer tissues were 
tested, it is difficult to explain the association between the BRAF 
V600E mutation and breast cancer based on these results. There-
fore, further research is needed to test for BRAF mutations in 
breast cancer tissue and ER and HER2 expression in thyroid can-
cer tissue to investigate the association between the BRAF V600E 
mutation and breast cancer. In a recent study published by Jung et 
al. [30], 230 patients with thyroid and breast cancer were screened 
for the BRAF V600E mutation in breast tissue, and an association 
was found between the BRAF mutation and ER+ breast cancer. 
However, the study reported no association between the BRAF 
mutation and cancer prognosis, indicating additional research is 
necessary.
The survival analysis of the first cancer among the two types of 
cancer (index tumor) showed that the length of the survival period 
was in the order of TB > BT > S, and the survival period was pre-
dicted to be longer for the patient groups in which the two cancers 
developed at different times (TB or BT) than the group in which 
they developed simultaneously (S). Differences in outcomes due to 
different pathogeneses of the two cancers, and the higher likeli-
hood of developing a secondary cancer among long-term survi-
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vors than short-term survivors due to time-related reasons may 
explain why the survival period was shorter in the S group. In ad-
dition, differences in the outcomes between the two cancers may 
have contributed to the longer survival rate of the TB group com-
pared to the BT group. Because thyroid cancer generally has a bet-
ter prognosis than breast cancer, breast cancer may have affected 
the prognoses of both the BT and TB groups more significantly 
than did thyroid cancer. Breast cancers showed the smaller breast 
tumor size, less lymphnode invasion, and the lower TNM stage in 
the BT than the TB group, thus prognoses was better in the BT than 
the TB group. No significant differences were found between the 
survival curves of breast and thyroid cancer. However, as the sur-
vival analysis was limited due to the small sample size and the rela-
tively short follow-up period, additional investigation is necessary.
The present study has a number of limitations. First, it is a retro-
spective study, and as a result, there were some missing clinical 
data. Moreover, this study may have been affected by selection bias 
because the data were collected from a single institution only. In 
addition, the relatively short follow-up period for thyroid cancer 
and breast cancer, which have high survival rates, limited the sur-
vival analysis. Lastly, a multivariate survival analysis in which the 
data were adjusted for cancer stage was not performed, and the 
30,000 patients who underwent treatment for breast cancer or thy-
roid cancer only were not analyzed. After a longer period of fol-
low-up, there will eventually be patients who develop secondary 
cancers, and thus, long-term follow-up is necessary. We minimized 
omission bias by thoroughly reviewing medical records, and the 
results of our study will be useful to guide future research. 
This study divided the patients with breast cancer and thyroid 
cancer, which are the most common cancers among women, into 
three groups according to those cancers’ occurrence order and 
compared the characteristics of the two cancer types. The rate of 
early detection of secondary cancer was significantly high for both 
patients who developed secondary breast cancer following thyroid 
cancer and patients who developed breast cancer followed by sec-
ondary thyroid cancer, highlighting the importance of postopera-
tive follow-up and regular medical examinations. However, the sig-
nificant differences in the rate of ER+ breast cancer and the differ-
ent proportions of patients who underwent preoperative chemo-
therapy among the groups suggests the need for additional investi-
gation into the pathological mechanism of secondary breast and 
thyroid cancer associated with primary breast and thyroid cancer. 
Although interpretation of the results of this study may be limited 
due to the small sample size used, the differences in the length of 
survival between the TB and BT groups suggests that thyroid can-
cer and breast cancer develop via different mechanisms and result 
in different outcomes depending on the order in which they devel-
op. Analysis of the characteristics of patients who experienced both 
thyroid cancer and breast cancer may contribute to the develop-
ment of cancer patient screening and follow-up programs and the 
establishment of guidelines for national cancer policies. 
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